In testimony to the Boulder County Commission, Val Giddings said it is the best way to safely meet their established sustainability goals to the benefit of consumers, farmers, and the environment.
Testimonies & Filings
February 15, 2016
In testimony to the U.S. ITC, Stephen Ezell explains why biotech is a key driver of both the U.S. economy and global life sciences innovation, and he argues robust IP standards in the TPP will be critical to both.
January 19, 2016
Comments to DoD, GSA, and NASA on Proposed Rule to Eliminate Proprietary Identifiers in Federal Acquisition Regulation
ITIF's Center for Data Innovation has filed comments supporting the proposed rule change as a critical first step towards making federal spending data truly open.
December 21, 2015
Under the current light-touch rules on mobile messaging, carriers have created a valuable, virtually spam-free service for consumers, and the FCC should maintain this regulatory environment.
December 17, 2015
ITIF’s Center for Data Innovation submitted comments to the European Commission urging it to do more to unlock the potential of data-driven innovation in online platforms.
December 10, 2015
Online platforms create immense social value by making it easier for their users to find each other and engage in mutually beneficial arrangements, explained ITIF in comments filed with the United Kingdom’s House of Lords.
December 8, 2015
While many parts of the Trans-Pacific Partnership agreement will positively impact bio innovation, others will inhibit the development of the next generation of breakthrough medicines, said Stephen Ezell in testimony before the House Ways and Means Committee Democratic Members.
November 20, 2015
ITIF's Center for Data Innovation has filed comments describing how OMB should build upon its proposed revisions to include policies that would maximize the value of open government data to the economy and society.
November 5, 2015
In comments to the White House Office of Science and Technology Policy, ITIF's Val Giddings argues there is no relationship between the degree of regulatory scrutiny a biotechnology product receives and the degree of hazard it represents.
November 4, 2015
Businesses that slip non-disparagement clauses into their consumer contracts are silencing critical public feedback, argued Rob Atkinson in testimony today before the Senate Commerce Committee.